Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$56.27 - $73.77 $6.19 Million - $8.11 Million
-110,000 Reduced 85.8%
18,200 $1.26 Million
Q4 2023

Feb 14, 2024

SELL
$59.06 - $75.72 $401,608 - $514,896
-6,800 Reduced 5.04%
128,200 $9.48 Million
Q3 2023

Nov 14, 2023

BUY
$65.94 - $99.04 $8.9 Million - $13.4 Million
135,000 New
135,000 $9.21 Million
Q2 2019

Aug 14, 2019

SELL
$89.51 - $118.04 $4.48 Million - $5.9 Million
-50,000 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$61.98 - $96.5 $3.78 Million - $5.89 Million
-61,000 Reduced 54.95%
50,000 $4.33 Million
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $616,440 - $909,260
11,000 Added 11.0%
111,000 $7 Million
Q3 2018

Nov 14, 2018

BUY
$48.29 - $80.6 $4.83 Million - $8.06 Million
100,000 New
100,000 $7.89 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $12B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.